Find a Research Study

Renal Disease Research Institute (RDRI) is a research entity affiliated with Dallas Nephrology Associates. For over 45 years, Dallas Nephrology Associates has been caring for patients with kidney disease, hypertension, transplants and complicated electrolyte disorders. The Research Institute allows us to conduct clinical trials that will improve our future ability to treat kidney disease and give our patients the opportunity to receive cutting edge therapy.  At RDRI, there is significant ethical oversight of this entity through RDRI’s Board of Managers and Scientific Review Committee.

Choosing to participate in a study is an important personal decision. Are you interested in participating in a study?  Talk with your doctor and family members or friends about deciding to join a study.

We are currently enrolling patients with the following conditions:
  • Autosomal dominant polycystic kidney disease
  • Immunoglobulin A (IgA) nephropathy
  • Assess cardio-renal outcomes in patients with chronic kidney disease
  • Treatment of immunoglobulin A nephropathy
  • Primary IGA nephropathy at risk of progressing to end-stage renal disease
  • Patients with chronic kidney disease (Stage II or III)
  • Chronic active antibody-mediated rejection in kidney transplant recipients

Indication: Autosomal Dominant Polycystic Kidney Disease 

Protocol Name: A phase 3 trial of the efficacy and safety of bardoxolone methyl in patients with autosomal dominant polycystic kidney disease. (Falcon)

Principal Investigator: Dr. Ankit Mehta

Location: 1420 Viceroy Drive, Dallas, TX 75235

Indication: Immunoglobulin A (IgA) Nephropathy

Protocol Name: A randomized, double-blind, placebo-controlled, phase 3 study of the safety and efficacy of OMS721 in patients with immunoglobulin A (IgA) nephropathy (ARTEMIS-IGAN). (Omeros)

Principal Investigator: Dr. Harold Szerlip

Location: Landry Tower, 411 N Washington Ave Ste 7000 Dallas, TX 75246

Indication: Assess cardio-renal outcomes in patients with chronic KIDNEY disease

Protocol Name: A multi-center international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease. (EMPA STUDY)

Principal Investigator: Dr. Harold Szerlip

Location: Landry Tower, 411 N Washington Ave Ste 7000 Dallas, TX 75246

Indication: Treatment of Immunoglobulin A Nephropathy

Protocol Name: A Randomized, multi-center, double-blind, parallel-group, active-control study of the efficacy and safety of sparsentan for the treatment of immunoglobulin A nephropathy.  (Protect Study)

Principal Investigator: Dr. Harold Szerlip

Location:Landry Tower, 411 N Washington Ave Ste 7000 Dallas, TX 75246

Indication: Patients with Chronic Kidney Disease (Stage II or III)

Protocol Name: A multi-center open-label investigation to assess the safety and efficacy of multiple doses of DM199 in patients with chronic kidney disease (Stage II or III). (Diamedica)

Principal Investigator: Dr. Venkata Yalamanchilli

Location: 2651 Bolton Boone Dr. DeSoto, TX 75115

Indication: Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients 

Protocol Name: Clinical study protocol A pivotal phase 3 trial to evaluate the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in kidney transplant recipients. (Vitaeris Study)

Principal Investigator: Dr. Bernard Fischbach

Location: 1420 Viceroy Drive, Dallas, TX 75235